louisiana glp-1 gastroparesis law office Lawsuit against makers of Ozempic, Mounjaro claims meds caused 'stomach paralysis' Weight Loss Drugs Lawsuit |

Ozempic Isnt Just For Diabetes

The majority of T2D management is in primary care, where clinicians (medical, nursing and pharmacist staff) play an important role in addressing patient needs and achieving treatment goals

The CEO of the Alliance for Pharmacy Compounding unpacks how the ruling affects telehealth providers and what it could signal for future GLP-1 entrants and market dynamics:

Euglycemic diabetic ketoacidosis (DKA), a side effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors, is a triad of high metabolic anion gap acidosis, raised serum and urine ketones, and serum glucose <250 mg/dl

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injective anti-diabetic drugs that improve glycemic control and many other atherosclerosis-related parameters in patients with type 2 diabetes (T2D)

Stopping treatment with weight loss medications is associated with gradual weight gain and a loss of earlier improvements in heart and metabolic he